We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-4.33%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.5B
AUM Growth
-$794M
Cap. Flow
+$217M
Cap. Flow %
1.89%
Top 10 Hldgs %
81.68%
Holding
128
New
8
Increased
22
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$146M
2
ABLX
Ablynx NV
ABLX
+$94M
3
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$73M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$54.2M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$45M

Top Sells

Rank Stock Value
1
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$170M
2
AKAO
Achaogen Inc
AKAO
+$47.2M
3
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$22.2M
4
EXEL icon
Exelixis
EXEL
+$15.3M
5
LOXO
Loxo Oncology, Inc
LOXO
+$8.85M

Sector Composition

Rank Sector Weight
1 Healthcare 93.21%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
51
Nektar Therapeutics
NKTR
$2.31B
$10.3M 0.09%
+11,462
New +$6.78M
LGND icon
52
Ligand Pharmaceuticals
LGND
$5.76B
$10M 0.09%
117,638
– –
STML
53
DELISTED
Stemline Therapeutics, Inc.
STML
$9.88M 0.09%
633,497
– –
RIGL icon
54
Rigel Pharmaceuticals
RIGL
$712M
$9.77M 0.08%
251,888
– –
CBIO
55
Crescent Biopharma
CBIO
$566M
$9.46M 0.08%
5,633
– –
QURE icon
56
uniQure
QURE
$2.76B
$9.45M 0.08%
+482,557
New +$7.35M
ITCI
57
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$8.82M 0.08%
609,166
– –
ACHN
58
DELISTED
Achillion Pharmaceuticals
ACHN
$8.23M 0.07%
2,856,637
+1,000,000
+54% +$3.63M
ALKS icon
59
Alkermes
ALKS
$8.08B
$8.22M 0.07%
150,251
– –
LUMO
60
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$8.17M 0.07%
111,919
– –
AGIO icon
61
Agios Pharmaceuticals
AGIO
$2.08B
$7.36M 0.06%
128,666
– –
CFRX
62
DELISTED
ContraFect Corporation
CFRX
$7.22M 0.06%
8,941
– –
XLRN
63
DELISTED
Acceleron Pharma
XLRN
$6.96M 0.06%
163,900
– –
MGNX icon
64
MacroGenics
MGNX
$235M
$6.91M 0.06%
363,676
– –
VNDA icon
65
Vanda Pharmaceuticals
VNDA
$301M
$6.44M 0.06%
423,884
– –
SYRE icon
66
Spyre Therapeutics
SYRE
$8.26B
$6.16M 0.05%
45,515
– –
TTPH
67
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$5.89M 0.05%
46,750
– –
ADMS
68
DELISTED
Adamas Pharmaceuticals
ADMS
$5.85M 0.05%
172,630
– –
NBRV
69
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$5.61M 0.05%
3,753
– –
SYRS
70
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.59M 0.05%
57,484
– –
ALBO
71
DELISTED
Albireo Pharma Inc
ALBO
$5.12M 0.04%
200,000
– –
FSTX
72
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$5.01M 0.04%
93,286
– –
LJPC
73
DELISTED
La Jolla Pharmaceutical Company
LJPC
$4.98M 0.04%
154,675
– –
GNMX
74
DELISTED
Aevi Genomic Medicine Inc
GNMX
$4.87M 0.04%
4,055,142
-491,284
-11% -$671K
CMTA
75
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$4.75M 0.04%
250,000
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Baker Bros. Advisors held 128 positions worth $11.5B, down 6.4% from $12.3B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Baker Bros. Advisors's Q4 2017 filing shows 8 new, 22 increased, 12 reduced and 5 closed positions. Its largest new stake was Ablynx NV: 4,161,118 shares worth $104M. The largest sale was Advanced Accelerator Applications S.A., an estimated $170M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q4 2017 buy was Ablynx NV: 4,161,118 shares worth $104M.
  • Baker Bros. Advisors added most to BioMarin Pharmaceuticals in Q4 2017, an estimated $146M increase.
  • Baker Bros. Advisors's biggest Q4 2017 reduction was Advanced Accelerator Applications S.A., cutting an estimated $170M.
  • Baker Bros. Advisors fully exited NeuroDerm Ltd. Ordinary Shares in Q4 2017, selling an estimated $22.2M.
  • Baker Bros. Advisors's ten largest holdings make up 82% of its $11.5B portfolio in Q4 2017.
  • Baker Bros. Advisors opened 8 new positions and closed 5 in Q4 2017.
  • Baker Bros. Advisors's portfolio value fell 6.4% quarter-over-quarter to $11.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.